<meta http-equiv="content-type" content="text/html; charset=ISO-8859-1" />
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8" >
<br>Title: Brand Drug Distribution: Fee-for-Service vs. Direct-to-Pharmacy</br><br>Author: Yao Zhao, Associate Professor, Rutgers Business School, 1 Washington Park, Newark, NJ, 07102, United States of America, yaozhao@andromeda.rutgers.edu</br><br>Coauthor(s): Katie Lacocca, Adam Fein</br><br>Year: 2012</br><br>Abstract: The U.S. pharmaceutical supply chain is under drastical transformation from asset-based Fee-for-Service agreement to Direct-to-Pharmacy agreement that transfers the ownership of channel inventory to the manufacturer. Such a transition generated a heavy debate among industry observers. Using mathematic models and real world examples, we compare these agreements for the pharmaceutical supply chain as a whole and its individual participants.</br>